A Medical Device Daily
FASgen (Baltimore) reported receiving an SBIR grant from the National Cancer Institute, a unit of the National Institutes of Health, for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS-Detect ELISA. The company describes the test as an "excellent signal" signal for identifying FAS that is over-expressed by most cancers and circulates in the blood of cancer patients.
The amount of the grant was not disclosed.
FASgen says that its therapeutic solution is a series of novel small molecule FAS inhibitors that display efficacy against many types of human cancers in animal models, affording, it said, "a new and remarkable opportunity for cancer detection and the identification of patients that will be responsive to the company's anti-cancer therapy."
FAS-Detect is a product of FASgen Diagnostics, an affiliate of FASgen, with the research the result of more than 15 years of efforts between it at The Johns Hopkins University School of Medicine (Baltimore). FASgen was founded seven years ago, based upon discoveries made at Hopkins.
The company said that the award supports ongoing work in the refinement of the current ELISA research test to differentiate FAS derived from cancer from FAS elaborated from normal tissues that occur in some diseases unrelated to cancer. The company's current ELISA format identifies the over-expression of FAS in the blood of cancer patients and is sensitive to 1.6 ng./ml. FAS-Detect is available for research purposes .
"The refinement of the serum FAS assay will significantly aid oncologists with earlier and better diagnostic information to assist in the treatment of patients. With the arrival of the FASgen therapeutic product, there will then be another highly specific tool in the oncologists' arsenal for treatment of the disease," said Eric Stoer, FASgen CEO and chairman.